Acumen Pharmaceuticals, Inc.

Contributing Author

Recent Articles by Acumen Pharmaceuticals, Inc.

Aug-12	Acumen Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Highlights ABOS GlobeNewswire
Aug-05	Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 12, 2026 ABOS GlobeNewswire
Jul-15	Acumen Pharmaceuticals Highlights Enhanced Brain Delivery (EBD) Program Data and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC) 2026 ABOS -12.25% GlobeNewswire
Jul-07	Acumen Pharmaceuticals to Present Data on Enhanced Brain Delivery (EBD) Technology and Early Alzheimer's Disease Insights at the Alzheimer's Association International Conference (AAIC) 2026 ABOS GlobeNewswire
Jun-16	Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery (EBD) Development Candidates for the Treatment of Alzheimer's Disease ABOS GlobeNewswire
May-12	Acumen Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Highlights ABOS GlobeNewswire
May-07	Acumen Pharmaceuticals to Participate in the Bank of America Securities 2026 Health Care Conference ABOS GlobeNewswire
May-05	Acumen Pharmaceuticals to Report First Quarter Financial Results on May 12, 2026 ABOS GlobeNewswire
Mar-26	Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights ABOS GlobeNewswire
Mar-19	Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2025 Financial Results on March 26, 2026 ABOS ABOS -8.56% GlobeNewswire
Mar-17	Acumen Pharmaceuticals Presents Studies on Enhanced Brain Delivery, Biomarker Research, and Novel Antibodies at Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 ABOS -7.49% GlobeNewswire
Mar-16	Acumen Pharmaceuticals Announces $35.75 Million Private Placement to Advance Potential Best-in-Class Molecules from Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio ABOS GlobeNewswire
Mar-10	Acumen Pharmaceuticals to Participate in the Stifel 2026 Virtual CNS Forum ABOS +7.01% GlobeNewswire
Mar-03	Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer's and Parkinson's Diseases 2026 ABOS GlobeNewswire
Dec-02	Acumen Pharmaceuticals Highlights Enhanced Brain Delivery Technology for Oligomer-Selective Antibodies and Recruitment Strategies for Phase 2 ALTITUDE-AD Clinical Trial at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference ABOS -7.89% GlobeNewswire
Nov-18	Acumen Pharmaceuticals to Present on Recruitment Strategies for Phase 2 ALTITUDE-AD Trial and Enhanced Brain Delivery Technology at 18th Annual Clinical Trials on Alzheimer's Disease (CTAD) Conference ABOS +5.06% GlobeNewswire
Nov-17	Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer's Disease ABOS -8.67% GlobeNewswire
Nov-12	Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights ABOS GlobeNewswire
Nov-10	Acumen Pharmaceuticals Appoints George Golumbeski, Ph.D., as Chairman of its Board of Directors ABOS GlobeNewswire
Nov-05	Acumen Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 12, 2025 ABOS ABOS -6.40% GlobeNewswire
Nov-04	Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference ABOS -11.01% GlobeNewswire
Aug-26	Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences ABOS GlobeNewswire
Aug-12	Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights ABOS -11.27% GlobeNewswire
Aug-05	Acumen Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 12, 2025 ABOS GlobeNewswire
Jul-28	Acumen Pharmaceuticals Presents Studies Showing the Utility of a pTau217 Assay in Screening for a Phase 2 Alzheimer's Disease Trial and Validates Sabirnetug Oligomer-Selectivity, at the Alzheimer's Association International Conference (AAIC) 2025 ABOS -7.01% GlobeNewswire
Jul-15	Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery Therapy for Alzheimer's Disease ABOS -12.08% GlobeNewswire
Jul-10	Acumen Pharmaceuticals to Present Studies on Cost Savings Associated with Use of pTau217 Screening Assay in Phase 2 ALTITUDE-AD Study and Sabirnetug Oligomer-Selectivity at the Alzheimer's Association International Conference (AAIC) 2025 ABOS GlobeNewswire
May-13	Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights ABOS GlobeNewswire
May-07	Acumen Pharmaceuticals to Participate in the Bank of America Healthcare Conference ABOS GlobeNewswire
May-06	Acumen Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025 ABOS GlobeNewswire

Acumen Pharmaceuticals, Inc.

Recent Articles by Acumen Pharmaceuticals, Inc.

Upgrade your Finviz experience